Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16644147 | 0.93 | NPC1 (0.55) | MAPTALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL16660774 | 0.88 | KMT2A (0.48) | MAPTALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL16646641 | 0.86 | ALDH1A1 (0.47) | MAPTALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL23838607 | 0.80 | KMT2A (0.54) | MAPTALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL9823025 | 0.79 | NPC1 (0.75) | MAPTALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL16644172 | 0.78 | NQO2 (0.46) | MAPTALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL24920215 | 0.74 | NPC1 (0.54) | MAPTALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL23838593 | 0.74 | NPC1 (0.46) | MAPTALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL24541019 | 0.74 | NPC1 (0.50) | MAPTALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL26260604 | 0.74 | NPC1 (0.62) | MAPTALDH1A1NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150141646-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | Concortis Biosystems, Corp., a wholly owned subsidary of Sorrento Therapeutics, Inc, (US) | 2015-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141646-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | ABCG2, UGT2B7, UGT1A9 | MAPT 1089/4885ALDH1A1 154/4885NPC1 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.